Latest Breaking News On - Adjuvant treatment - Page 1 : comparemela.com

AstraZeneca furthers ambition to transform outcomes in early lung cancer and redefine metastatic breast cancer treatment at ASCO 2024

AstraZeneca furthers ambition to transform outcomes in early lung cancer and redefine metastatic breast cancer treatment at ASCO 2024
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesSusan galbraithDave fredricksonDaiichi sankyo incDaiichi sankyo companyMerck co incAbelzeta pharmaceuticals incAmerican society of clinical oncologyAmerican societyClinical oncologyAnnual meetingRapid oral abstractExecutive vice presidentOncology business unitAbelzeta pharmaceuticals

Phase 2 data for ERLEADA® ▼(apalutamide) plus androgen

Study highlights opportunity for treatment intensification in this population since approximately 50 percent of patients with high-risk localised prostate.

United statesRegion flamandeSan antonioHenar heviaLuca dezzaniExchange commissionJanssen research developmentAmerican urological association annual meetingSteering committeeJanssen cilag internationalNone of janssen cilag internationalEuropean medicines agencyJanssen cilag international nv incOral presentation sessionUrological association annual meetingSteering committee chair

Merck Announces First-Quarter 2024 Financial Results

Sales Reflect Continued Strong Growth in Oncology and Vaccines Total Worldwide Sales Were $15.8 Billion, an Increase of 9% From First Quarter 2023; Excluding the Impact of Foreign Exchange,.

United statesAdempas verquvoRaludotatug deruxtecanRobertm davisDaiichi sankyoHarpoon therapeutics incEuropean commission approved merckAlliance revenueGilead sciences incWorld health organization groupAnimal healthEuropean unionDrug administrationElanco animal health incorporatedStatement of merck co incNet income attributable to merck co inc

New Results From One Of The World s Largest Breast Cancer Trials Offer Hope To Thousands Of Women

LONDON, December 14 /PRNewswire/ - The Benefits of Anastrozole (Arimidex(R)) Over Tamoxifen at Preventing Breast Cancer Recurrence Improve Over Time - Up to Four Years After Treatment Ends New data from ATAC(x), one of the world s largest and longest-running studies in postmenopausal women with hormone receptor positive (HR+), early breast cance

United kingdomCity ofEast sussexSan antonioUnited statesAnthony howellAnastrozole arimidexChiara charkhamLesley fallowfieldAstrazeneca united kingdom ltdBreast cancer researchUniversity of sussexTrialist groupCancer research united kingdomCancer research united kingdom psychosocial oncology groupOver tamoxifen

European Commission Approves Merck s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Cancer (NSCLC) at High Risk of Recurrence in Adults

European Commission Approves Merck s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Cancer (NSCLC) at High Risk of Recurrence in Adults
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

United statesSolange petersExchange commissionEuropean commissionEuropean commission approves merckProduct serviceMerck co incCommittee for medicinal products humanStatement of merck co incCentre hospitalier universitaire vaudoisMerck research laboratoriesNeoadjuvant treatmentThen continuedAdjuvant treatmentResectable non small cell lung cancerHigh risk